Skin Cancer Treatment Market By Type (Melanoma, Non-Melanoma), By Therapy (Immunotherapy, Targeted Therapy, Chemotherapy), By Distribution Channel (Hospitals Pharmacies, Drug Stores and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031

Skin Cancer Treatment Market

Skin cancer is the most prevalent type of cancer across the globe. Melanoma or non-melanoma skin cancer (NMSC) are the two main categories of skin cancer. Due to inadequate diagnostic standards and underreporting, it is challenging to pinpoint the exact incidences of skin cancer. Head and neck are common areas where skin malignancies are found, which can cause serious morbidity during diagnosis and treatment. Medicated treatment options include chemotherapy, immunotherapy, and targeted therapy. Sunscreen use is essential for proper sun safety. The primary etiological component in the emergence of cutaneous cancers is ultraviolet (UV) sun radiation. Majority of NMSC and melanoma cases can be attributed to UV exposure.

Increase in prevalence of skin cancer cases including melanoma and non-melanoma are the major factors contributes, to drive the growth of skin cancer treatment market size. For instance, according to the Skin Cancer Foundation, U.S. has reported about 3.6 million populations with basal cell carcinoma and 1.8 million people with squamous cell carcinoma in 2022. From the same report it was estimated that, skin cancer is most common type of cancer in the U.S. 1 in 5 Americans will develop skin cancer and more than 2 people die with skin cancer.

In addition, increase in initiative taken by government and key players involved in manufacturing and development of innovative therapeutics in the healthcare sector for effective treatment of skin cancer are some skin cancer treatment market trends leads to the market growth.  For instance, in 2020, Genentech, a member of leading pharmaceutical company Roche announced the product approval from Food and Drug Administration (FDA) for products Tecentriq (atezolizumab) and Cotellic (cobimetinib) collectively to treat patients with BRAF V600 mutation effectively.  

Furthermore, rise in product approvals for effective management of skin cancer by regulatory authorities also boost the market growth. For instance, in 2021, the FDA announced approval of the first immunotherapy product, PD-1 inhibitor Libtayo to treat basal cell carcinoma, which has a higher chance of success than the previously used hedgehog pathway inhibitor (HHI). Increased demand for immunotherapy and targeted based therapy treatments and increased awareness about skin cancer treatments are the opportunities for market growth in forecast period. However, side effects associated with use of chemotherapy for skin cancer treatment hampers the market growth.

COVID-19 is a large family of viruses that causes illness ranging from common cold to more severe respiratory diseases. The global skin cancer treatment industry also declined in 2020 due to global economic recession led by COVID-19. The main factor is the delays in care, that patients with skin cancer experience in hospitals because of the possibility of contracting COVID-19 infection. The COVID-19 global public health crisis has had an effect on almost every industry.

The global skin cancer treatment market is segmented by type, therapy, distribution channel and region. By type, the market is classified into melanoma and non-melanoma. By therapy, the market is classified into immunotherapy, targeted therapy, and chemotherapy. By distribution channel, the market is classified into hospitals pharmacies, drug stores & retail pharmacies and online providers. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Depending on type, the market is divided into melanoma and non- melanoma. The melanoma segment dominated the market in 2021, and is also expected to witness highest CAGR during skin cancer treatment market forecast, owing to increase in number of populations affected with melanoma. The non-melanoma type segment is expected to grow during the forecast period, owing to increase in number of populations with non-melanoma and product launches for non-melanoma type of skin cancer treatment.

Depending on therapy, the market is divided into immunotherapy, targeted therapy, and chemotherapy. The immunotherapy segment dominated the market in 2021, and is also expected to witness highest CAGR during the forecast period, owing to increase in demand for immunotherapy-based skin cancer treatments and minimum side effects associated with use of immunotherapy drugs. The targeted therapy segment is estimated to grow during the forecast period, owing to increase in product launches, less side effects associated with targeted based therapies, higher efficacy, and accuracy.

Depending on distribution channel, the market is divided into hospital pharmacies, drug store & retail pharmacies and online providers. The drug stores & retail pharmacies segment dominated the market in 2021, owing to its presence in commercial areas of the community. The online provider segment is expected to witness highest CAGR of during the forecast period, owing to popular medium for purchase of medicines.

By region, North America accounted for majority of the global skin cancer treatment market share in 2021, and is anticipated to remain dominant during the forecast period. This is attributed to technological advancements in skin cancer treatment techniques, R & D of advanced drugs for allergic conjunctivitis and presence of key and robust hospital infrastructure in the region. However, Asia-Pacific is anticipated to witness notable growth, owing to rise in patient population, development of healthcare infrastructure, and increase in investment projects in the region.

KEY FINDINGS OF THE STUDY 

• By type, the melanoma segment was the highest contributor to the skin cancer treatment industry in 2021.

• By therapy, the immunotherapy segment was the highest contributor to the market in 2021.

• Depending on distribution channel, the drug stores & retail pharmacies segment was the highest contributor in 2021, and is expected to continue this trend during the forecast period.

• Region wise, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the skin cancer treatment market analysis.

Overview

Skin cancer is common type of cancer caused due to sun’s harmful radiation. The abnormal pigmentation, collagenosis, skin wrinkling, and solar keratosis on sun-exposed skin are the signs associated with skin cancer. There are two types of skin cancers including melanoma and non-melanoma. There are two types of non-melanoma cancers which includes basal cell carcinoma and squamous cell carcinoma. Non-melanocytic skin cancer is the most prevalent type of skin cancer detected in people which affects over 2-3 million people worldwide. There are several medicated treatments available for skin cancer which includes targeted therapy, chemotherapy, and immunotherapy.

Increase in prevalence of non-melanoma and melanoma type of skin cancer across the globe, availability of various skin cancer treatments, and increased demand for skin cancer treatment are the factors that positively influence the skin cancer treatment market growth. For instance, according to the American Cancer Society, in 2020, 5.4 million people were diagnosed with basal and squamous skin cancer in the U.S. each year and there are 2,000 people die with same cancer. As per the same source, estimated number of people suffering from basal and squamous skin cancer in U.S. is 3.3 million. The most common type of skin cancer frequently observed in American people is basal cell cancer with 8 out of 10 people.  Squamous cell cancer is less likely observed in American people. In addition, initiatives taken by governments for the management of skin cancer and key players involved in the manufacturing and development of the advanced therapies for the effective skin cancer treatment are the factor boost skin cancer treatment market. For instance, in 2020, Novartis AG announced COMBI-AD clinical trial for the products Tafinlar + Mekinist to treat stage III BRAF V600-mutated melanoma patients to provide surgery to provide efficient, long-term effect for those patients who have high risk of cancer recurrence. In addition, availability of hospital pharmacies and drugs, diagnostic centers and hospitals influence the market growth. However, side effects associated with use of chemotherapy and radiotherapy skin cancer treatment restrain the market growth. Rise in number of product approvals and emergence of advanced therapies for skin cancer treatment are opportunities for the market growth.

The global skin cancer treatment market is segmented on the basis of type, therapy, distribution channel, and region. By type, the market is classified into melanoma and non-melanoma. The non-melanoma segment is further segmented into basal cell carcinoma, squamous cell carcinoma, and others. By therapy, the market is classified into immunotherapy, targeted therapy, and chemotherapy. By distribution channel, it is classified into hospitals pharmacies, drug stores & retail pharmacies, and online providers. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Some of the major companies that operate in the global skin cancer treatment market are Amgen Inc, Bristol Myers Squibb Company, F. Hoffman–La-Roche Ltd, GlaxoSmithKline Plc., LEO Pharm A/S, Merck KGAA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals and, Sun Pharmaceutical Industries Ltd.

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the skin cancer treatment market analysis from 2021 to 2031 to identify the prevailing skin cancer treatment market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the skin cancer treatment market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global skin cancer treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

○ Sun Pharmaceutical Industries Ltd

Scope of Skin Cancer Treatment Market Report

1.1.Report description

1.2.Key market segments

1.3.Key benefits to the stakeholders

1.4.Research Methodology

1.4.1.Secondary research

1.4.2.Primary research

1.4.3.Analyst tools and models

2.1.Key findings of the study

2.2.CXO Perspective

3.1.Market definition and scope

3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five forces analysis

3.4.Top player positioning

3.5.Market dynamics

3.5.1.Drivers

3.5.2.Restraints

3.5.3.Opportunities

3.6.COVID-19 Impact Analysis on the market

3.7.Patent Landscape

4.1 Overview

4.1.1 Market size and forecast

4.2 Melanoma

4.2.1 Key market trends, growth factors and opportunities

4.2.2 Market size and forecast, by region

4.2.3 Market analysis by country

4.3 Non-Melanoma

4.3.1 Key market trends, growth factors and opportunities

4.3.2 Market size and forecast, by region

4.3.3 Market analysis by country

4.3.4 Non-Melanoma Skin Cancer Treatment Market by Type

4.3.4.1 Basal Cell Carcinoma Market size and forecast, by region

4.3.4.2 Squamous Cell Carcinoma Market size and forecast, by region

4.3.4.3 Others Market size and forecast, by region

5.1 Overview

5.1.1 Market size and forecast

5.2 Immunotherapy

5.2.1 Key market trends, growth factors and opportunities

5.2.2 Market size and forecast, by region

5.2.3 Market analysis by country

5.3 Targeted Therapy

5.3.1 Key market trends, growth factors and opportunities

5.3.2 Market size and forecast, by region

5.3.3 Market analysis by country

5.4 Chemotherapy

5.4.1 Key market trends, growth factors and opportunities

5.4.2 Market size and forecast, by region

5.4.3 Market analysis by country

6.1 Overview

6.1.1 Market size and forecast

6.2 Hospitals Pharmacies

6.2.1 Key market trends, growth factors and opportunities

6.2.2 Market size and forecast, by region

6.2.3 Market analysis by country

6.3 Drug Stores and Retail Pharmacies

6.3.1 Key market trends, growth factors and opportunities

6.3.2 Market size and forecast, by region

6.3.3 Market analysis by country

6.4 Online Providers

6.4.1 Key market trends, growth factors and opportunities

6.4.2 Market size and forecast, by region

6.4.3 Market analysis by country

7.1 Overview

7.1.1 Market size and forecast

7.2 North America

7.2.1 Key trends and opportunities

7.2.2 North America Market size and forecast, by Type

7.2.2.1 North America Non-Melanoma Skin Cancer Treatment Market by Type

7.2.3 North America Market size and forecast, by Therapy

7.2.4 North America Market size and forecast, by Distribution Channel

7.2.5 North America Market size and forecast, by country

7.2.5.1 U.S.

7.2.5.1.1 Market size and forecast, by Type

7.2.5.1.2 Market size and forecast, by Therapy

7.2.5.1.3 Market size and forecast, by Distribution Channel

7.2.5.2 Canada

7.2.5.2.1 Market size and forecast, by Type

7.2.5.2.2 Market size and forecast, by Therapy

7.2.5.2.3 Market size and forecast, by Distribution Channel

7.2.5.3 Mexico

7.2.5.3.1 Market size and forecast, by Type

7.2.5.3.2 Market size and forecast, by Therapy

7.2.5.3.3 Market size and forecast, by Distribution Channel

7.3 Europe

7.3.1 Key trends and opportunities

7.3.2 Europe Market size and forecast, by Type

7.3.2.1 Europe Non-Melanoma Skin Cancer Treatment Market by Type

7.3.3 Europe Market size and forecast, by Therapy

7.3.4 Europe Market size and forecast, by Distribution Channel

7.3.5 Europe Market size and forecast, by country

7.3.5.1 Germany

7.3.5.1.1 Market size and forecast, by Type

7.3.5.1.2 Market size and forecast, by Therapy

7.3.5.1.3 Market size and forecast, by Distribution Channel

7.3.5.2 France

7.3.5.2.1 Market size and forecast, by Type

7.3.5.2.2 Market size and forecast, by Therapy

7.3.5.2.3 Market size and forecast, by Distribution Channel

7.3.5.3 UK

7.3.5.3.1 Market size and forecast, by Type

7.3.5.3.2 Market size and forecast, by Therapy

7.3.5.3.3 Market size and forecast, by Distribution Channel

7.3.5.4 Italy

7.3.5.4.1 Market size and forecast, by Type

7.3.5.4.2 Market size and forecast, by Therapy

7.3.5.4.3 Market size and forecast, by Distribution Channel

7.3.5.5 Spain

7.3.5.5.1 Market size and forecast, by Type

7.3.5.5.2 Market size and forecast, by Therapy

7.3.5.5.3 Market size and forecast, by Distribution Channel

7.3.5.6 Rest of Europe

7.3.5.6.1 Market size and forecast, by Type

7.3.5.6.2 Market size and forecast, by Therapy

7.3.5.6.3 Market size and forecast, by Distribution Channel

7.4 Asia-Pacific

7.4.1 Key trends and opportunities

7.4.2 Asia-Pacific Market size and forecast, by Type

7.4.2.1 Asia-Pacific Non-Melanoma Skin Cancer Treatment Market by Type

7.4.3 Asia-Pacific Market size and forecast, by Therapy

7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel

7.4.5 Asia-Pacific Market size and forecast, by country

7.4.5.1 Japan

7.4.5.1.1 Market size and forecast, by Type

7.4.5.1.2 Market size and forecast, by Therapy

7.4.5.1.3 Market size and forecast, by Distribution Channel

7.4.5.2 China

7.4.5.2.1 Market size and forecast, by Type

7.4.5.2.2 Market size and forecast, by Therapy

7.4.5.2.3 Market size and forecast, by Distribution Channel

7.4.5.3 India

7.4.5.3.1 Market size and forecast, by Type

7.4.5.3.2 Market size and forecast, by Therapy

7.4.5.3.3 Market size and forecast, by Distribution Channel

7.4.5.4 Australia

7.4.5.4.1 Market size and forecast, by Type

7.4.5.4.2 Market size and forecast, by Therapy

7.4.5.4.3 Market size and forecast, by Distribution Channel

7.4.5.5 South Korea

7.4.5.5.1 Market size and forecast, by Type

7.4.5.5.2 Market size and forecast, by Therapy

7.4.5.5.3 Market size and forecast, by Distribution Channel

7.4.5.6 Rest of Asia-Pacific

7.4.5.6.1 Market size and forecast, by Type

7.4.5.6.2 Market size and forecast, by Therapy

7.4.5.6.3 Market size and forecast, by Distribution Channel

7.5 LAMEA

7.5.1 Key trends and opportunities

7.5.2 LAMEA Market size and forecast, by Type

7.5.2.1 LAMEA Non-Melanoma Skin Cancer Treatment Market by Type

7.5.3 LAMEA Market size and forecast, by Therapy

7.5.4 LAMEA Market size and forecast, by Distribution Channel

7.5.5 LAMEA Market size and forecast, by country

7.5.5.1 Brazil

7.5.5.1.1 Market size and forecast, by Type

7.5.5.1.2 Market size and forecast, by Therapy

7.5.5.1.3 Market size and forecast, by Distribution Channel

7.5.5.2 Saudi Arabia

7.5.5.2.1 Market size and forecast, by Type

7.5.5.2.2 Market size and forecast, by Therapy

7.5.5.2.3 Market size and forecast, by Distribution Channel

7.5.5.3 South Africa

7.5.5.3.1 Market size and forecast, by Type

7.5.5.3.2 Market size and forecast, by Therapy

7.5.5.3.3 Market size and forecast, by Distribution Channel

7.5.5.4 Rest of LAMEA

7.5.5.4.1 Market size and forecast, by Type

7.5.5.4.2 Market size and forecast, by Therapy

7.5.5.4.3 Market size and forecast, by Distribution Channel

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Key developments

9.1 Amgen Inc.

9.1.1 Company overview

9.1.2 Company snapshot

9.1.3 Operating business segments

9.1.4 Product portfolio

9.1.5 Business performance

9.1.6 Key strategic moves and developments

9.2 Bristol-Myers Squibb

9.2.1 Company overview

9.2.2 Company snapshot

9.2.3 Operating business segments

9.2.4 Product portfolio

9.2.5 Business performance

9.2.6 Key strategic moves and developments

9.3 F. Hoffmann-La Roche

9.3.1 Company overview

9.3.2 Company snapshot

9.3.3 Operating business segments

9.3.4 Product portfolio

9.3.5 Business performance

9.3.6 Key strategic moves and developments

9.4 Glaxosmithkline plc

9.4.1 Company overview

9.4.2 Company snapshot

9.4.3 Operating business segments

9.4.4 Product portfolio

9.4.5 Business performance

9.4.6 Key strategic moves and developments

9.5 LEO Pharma

9.5.1 Company overview

9.5.2 Company snapshot

9.5.3 Operating business segments

9.5.4 Product portfolio

9.5.5 Business performance

9.5.6 Key strategic moves and developments

9.6 Merck KGaA

9.6.1 Company overview

9.6.2 Company snapshot

9.6.3 Operating business segments

9.6.4 Product portfolio

9.6.5 Business performance

9.6.6 Key strategic moves and developments

9.7 Novartis AG

9.7.1 Company overview

9.7.2 Company snapshot

9.7.3 Operating business segments

9.7.4 Product portfolio

9.7.5 Business performance

9.7.6 Key strategic moves and developments

9.8 Pfizer Inc.

9.8.1 Company overview

9.8.2 Company snapshot

9.8.3 Operating business segments

9.8.4 Product portfolio

9.8.5 Business performance

9.8.6 Key strategic moves and developments

9.9 Regeneron Pharmaceuticals, Inc.

9.9.1 Company overview

9.9.2 Company snapshot

9.9.3 Operating business segments

9.9.4 Product portfolio

9.9.5 Business performance

9.9.6 Key strategic moves and developments

9.10 Sun Pharmaceutical Industries Ltd.

9.10.1 Company overview

9.10.2 Company snapshot

9.10.3 Operating business segments

9.10.4 Product portfolio

9.10.5 Business performance

9.10.6 Key strategic moves and development

LIST OF TABLES

TABLE 1. GLOBAL SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 2. SKIN CANCER TREATMENT MARKET, FOR MELANOMA, BY REGION, 2021-2031 ($MILLION)

TABLE 3. SKIN CANCER TREATMENT MARKET FOR MELANOMA, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 4. SKIN CANCER TREATMENT MARKET, FOR NON-MELANOMA, BY REGION, 2021-2031 ($MILLION)

TABLE 5. SKIN CANCER TREATMENT MARKET FOR NON-MELANOMA, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 6. GLOBAL NON-MELANOMA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 7. SKIN CANCER TREATMENT MARKET, FOR BASAL CELL CARCINOMA, BY REGION, 2021-2031 ($MILLION)

TABLE 8. SKIN CANCER TREATMENT MARKET, FOR SQUAMOUS CELL CARCINOMA, BY REGION, 2021-2031 ($MILLION)

TABLE 9. SKIN CANCER TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)

TABLE 10. GLOBAL SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)

TABLE 11. SKIN CANCER TREATMENT MARKET, FOR IMMUNOTHERAPY, BY REGION, 2021-2031 ($MILLION)

TABLE 12. SKIN CANCER TREATMENT MARKET FOR IMMUNOTHERAPY, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 13. SKIN CANCER TREATMENT MARKET, FOR TARGETED THERAPY, BY REGION, 2021-2031 ($MILLION)

TABLE 14. SKIN CANCER TREATMENT MARKET FOR TARGETED THERAPY, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 15. SKIN CANCER TREATMENT MARKET, FOR CHEMOTHERAPY, BY REGION, 2021-2031 ($MILLION)

TABLE 16. SKIN CANCER TREATMENT MARKET FOR CHEMOTHERAPY, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 17. GLOBAL SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 18. SKIN CANCER TREATMENT MARKET, FOR HOSPITALS PHARMACIES, BY REGION, 2021-2031 ($MILLION)

TABLE 19. SKIN CANCER TREATMENT MARKET FOR HOSPITALS PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 20. SKIN CANCER TREATMENT MARKET, FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)

TABLE 21. SKIN CANCER TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 22. SKIN CANCER TREATMENT MARKET, FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)

TABLE 23. SKIN CANCER TREATMENT MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 24. SKIN CANCER TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)

TABLE 25. NORTH AMERICA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 26. NORTH AMERICA NON-MELANOMA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 27. NORTH AMERICA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)

TABLE 28. NORTH AMERICA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 29. NORTH AMERICA SKIN CANCER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 30. U.S. SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 31. U.S. SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)

TABLE 32. U.S. SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 33. CANADA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 34. CANADA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)

TABLE 35. CANADA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 36. MEXICO SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 37. MEXICO SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)

TABLE 38. MEXICO SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 39. EUROPE SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 40. EUROPE NON-MELANOMA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 41. EUROPE SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)

TABLE 42. EUROPE SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 43. EUROPE SKIN CANCER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 44. GERMANY SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 45. GERMANY SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)

TABLE 46. GERMANY SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 47. FRANCE SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 48. FRANCE SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)

TABLE 49. FRANCE SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 50. UK SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 51. UK SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)

TABLE 52. UK SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 53. ITALY SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 54. ITALY SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)

TABLE 55. ITALY SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 56. SPAIN SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 57. SPAIN SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)

TABLE 58. SPAIN SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 59. REST OF EUROPE SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 60. REST OF EUROPE SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)

TABLE 61. REST OF EUROPE SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 62. ASIA-PACIFIC SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 63. ASIA-PACIFIC NON-MELANOMA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 64. ASIA-PACIFIC SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)

TABLE 65. ASIA-PACIFIC SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 66. ASIA-PACIFIC SKIN CANCER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 67. JAPAN SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 68. JAPAN SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)

TABLE 69. JAPAN SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 70. CHINA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 71. CHINA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)

TABLE 72. CHINA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 73. INDIA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 74. INDIA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)

TABLE 75. INDIA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 76. AUSTRALIA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 77. AUSTRALIA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)

TABLE 78. AUSTRALIA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 79. SOUTH KOREA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 80. SOUTH KOREA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)

TABLE 81. SOUTH KOREA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 82. REST OF ASIA-PACIFIC SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 83. REST OF ASIA-PACIFIC SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)

TABLE 84. REST OF ASIA-PACIFIC SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 85. LAMEA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 86. LAMEA NON-MELANOMA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 87. LAMEA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)

TABLE 88. LAMEA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 89. LAMEA SKIN CANCER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 90. BRAZIL SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 91. BRAZIL SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)

TABLE 92. BRAZIL SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 93. SAUDI ARABIA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 94. SAUDI ARABIA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)

TABLE 95. SAUDI ARABIA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 96. SOUTH AFRICA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 97. SOUTH AFRICA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)

TABLE 98. SOUTH AFRICA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 99. REST OF LAMEA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 100. REST OF LAMEA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)

TABLE 101. REST OF LAMEA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 102.AMGEN INC.: COMPANY SNAPSHOT

TABLE 103.AMGEN INC.: OPERATING SEGMENTS

TABLE 104.AMGEN INC.: PRODUCT PORTFOLIO

TABLE 105.AMGEN INC.: NET SALES,

TABLE 106.AMGEN INC.: KEY STRATERGIES

TABLE 107.BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT

TABLE 108.BRISTOL-MYERS SQUIBB: OPERATING SEGMENTS

TABLE 109.BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO

TABLE 110.BRISTOL-MYERS SQUIBB: NET SALES,

TABLE 111.BRISTOL-MYERS SQUIBB: KEY STRATERGIES

TABLE 112.F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT

TABLE 113.F. HOFFMANN-LA ROCHE: OPERATING SEGMENTS

TABLE 114.F. HOFFMANN-LA ROCHE: PRODUCT PORTFOLIO

TABLE 115.F. HOFFMANN-LA ROCHE: NET SALES,

TABLE 116.F. HOFFMANN-LA ROCHE: KEY STRATERGIES

TABLE 117.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT

TABLE 118.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS

TABLE 119.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO

TABLE 120.GLAXOSMITHKLINE PLC: NET SALES,

TABLE 121.GLAXOSMITHKLINE PLC: KEY STRATERGIES

TABLE 122.LEO PHARMA: COMPANY SNAPSHOT

TABLE 123.LEO PHARMA: OPERATING SEGMENTS

TABLE 124.LEO PHARMA: PRODUCT PORTFOLIO

TABLE 125.LEO PHARMA: NET SALES,

TABLE 126.LEO PHARMA: KEY STRATERGIES

TABLE 127.MERCK KGAA: COMPANY SNAPSHOT

TABLE 128.MERCK KGAA: OPERATING SEGMENTS

TABLE 129.MERCK KGAA: PRODUCT PORTFOLIO

TABLE 130.MERCK KGAA: NET SALES,

TABLE 131.MERCK KGAA: KEY STRATERGIES

TABLE 132.NOVARTIS AG: COMPANY SNAPSHOT

TABLE 133.NOVARTIS AG: OPERATING SEGMENTS

TABLE 134.NOVARTIS AG: PRODUCT PORTFOLIO

TABLE 135.NOVARTIS AG: NET SALES,

TABLE 136.NOVARTIS AG: KEY STRATERGIES

TABLE 137.PFIZER INC.: COMPANY SNAPSHOT

TABLE 138.PFIZER INC.: OPERATING SEGMENTS

TABLE 139.PFIZER INC.: PRODUCT PORTFOLIO

TABLE 140.PFIZER INC.: NET SALES,

TABLE 141.PFIZER INC.: KEY STRATERGIES

TABLE 142.REGENERON PHARMACEUTICALS, INC.: COMPANY SNAPSHOT

TABLE 143.REGENERON PHARMACEUTICALS, INC.: OPERATING SEGMENTS

TABLE 144.REGENERON PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO

TABLE 145.REGENERON PHARMACEUTICALS, INC.: NET SALES,

TABLE 146.REGENERON PHARMACEUTICALS, INC.: KEY STRATERGIES

TABLE 147.SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT

TABLE 148.SUN PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS

TABLE 149.SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO

TABLE 150.SUN PHARMACEUTICAL INDUSTRIES LTD.: NET SALES,

TABLE 151.SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES LIST OF FIGURES

FIGURE 1.SKIN CANCER TREATMENT MARKET SEGMENTATION

FIGURE 2.SKIN CANCER TREATMENT MARKET,2021-2031

FIGURE 3.SKIN CANCER TREATMENT MARKET,2021-2031

FIGURE 4. TOP INVESTMENT POCKETS, BY REGION

FIGURE 5.PORTER FIVE-1

FIGURE 6.PORTER FIVE-2

FIGURE 7.PORTER FIVE-3

FIGURE 8.PORTER FIVE-4

FIGURE 9.PORTER FIVE-5

FIGURE 10.TOP PLAYER POSITIONING

FIGURE 11.SKIN CANCER TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 12.PATENT ANALYSIS BY COMPANY

FIGURE 13.PATENT ANALYSIS BY COUNTRY

FIGURE 14.SKIN CANCER TREATMENT MARKET,BY TYPE,2021(%)

FIGURE 15.COMPARATIVE SHARE ANALYSIS OF MELANOMA SKIN CANCER TREATMENT MARKET,2021-2031(%)

FIGURE 16.COMPARATIVE SHARE ANALYSIS OF NON-MELANOMA SKIN CANCER TREATMENT MARKET,2021-2031(%)

FIGURE 17.SKIN CANCER TREATMENT MARKET,BY THERAPY,2021(%)

FIGURE 18.COMPARATIVE SHARE ANALYSIS OF IMMUNOTHERAPY SKIN CANCER TREATMENT MARKET,2021-2031(%)

FIGURE 19.COMPARATIVE SHARE ANALYSIS OF TARGETED THERAPY SKIN CANCER TREATMENT MARKET,2021-2031(%)

FIGURE 20.COMPARATIVE SHARE ANALYSIS OF CHEMOTHERAPY SKIN CANCER TREATMENT MARKET,2021-2031(%)

FIGURE 21.SKIN CANCER TREATMENT MARKET,BY DISTRIBUTION CHANNEL,2021(%)

FIGURE 22.COMPARATIVE SHARE ANALYSIS OF HOSPITALS PHARMACIES SKIN CANCER TREATMENT MARKET,2021-2031(%)

FIGURE 23.COMPARATIVE SHARE ANALYSIS OF DRUG STORES AND RETAIL PHARMACIES SKIN CANCER TREATMENT MARKET,2021-2031(%)

FIGURE 24.COMPARATIVE SHARE ANALYSIS OF ONLINE PROVIDERS SKIN CANCER TREATMENT MARKET,2021-2031(%)

FIGURE 25.SKIN CANCER TREATMENT MARKET BY REGION,2021

FIGURE 26.U.S. SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)

FIGURE 27.CANADA SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)

FIGURE 28.MEXICO SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)

FIGURE 29.GERMANY SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)

FIGURE 30.FRANCE SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)

FIGURE 31.UK SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)

FIGURE 32.ITALY SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)

FIGURE 33.SPAIN SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)

FIGURE 34.REST OF EUROPE SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)

FIGURE 35.JAPAN SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)

FIGURE 36.CHINA SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)

FIGURE 37.INDIA SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)

FIGURE 38.AUSTRALIA SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)

FIGURE 39.SOUTH KOREA SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)

FIGURE 40.REST OF ASIA-PACIFIC SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)

FIGURE 41.BRAZIL SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)

FIGURE 42.SAUDI ARABIA SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)

FIGURE 43.SOUTH AFRICA SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)

FIGURE 44.REST OF LAMEA SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)

FIGURE 45. TOP WINNING STRATEGIES, BY YEAR

FIGURE 46. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 47. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 48.PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 49.COMPETITIVE DASHBOARD

FIGURE 50.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS

FIGURE 51.AMGEN INC..: NET SALES ,($MILLION)

FIGURE 52.BRISTOL-MYERS SQUIBB.: NET SALES ,($MILLION)

FIGURE 53.F. HOFFMANN-LA ROCHE.: NET SALES ,($MILLION)

FIGURE 54.GLAXOSMITHKLINE PLC.: NET SALES ,($MILLION)

FIGURE 55.LEO PHARMA.: NET SALES ,($MILLION)

FIGURE 56.MERCK KGAA.: NET SALES ,($MILLION)

FIGURE 57.NOVARTIS AG.: NET SALES ,($MILLION)

FIGURE 58.PFIZER INC..: NET SALES ,($MILLION)

FIGURE 59.REGENERON PHARMACEUTICALS, INC..: NET SALES ,($MILLION)

FIGURE 60.SUN PHARMACEUTICAL INDUSTRIES LTD..: NET SALES ,($MILLION